{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:21:36Z","timestamp":1783736496281,"version":"3.55.0"},"reference-count":39,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"VA Merit Award","award":["CX000369"],"award-info":[{"award-number":["CX000369"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To determine whether cellular matrix (CM) products result in better healing rates than acellular matrix (ACM) products for nonhealing diabetic foot ulcers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>The Dermagraft and Oasis Longitudinal Comparative Efficacy Study (DOLCE) was a randomized, single-blinded, three-arm controlled trial. Patients (aged \u226518 years) with a full-thickness nonhealing diabetic foot ulcer who met inclusion\/exclusion criteria were enrolled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of 169 eligible patients, 138 were enrolled and 117 randomly assigned. For 12 weeks, patients received standard of care (SOC), CM, or ACM. The primary outcome was the percentage of wounds healed by 12 weeks. Of the 117 participants, 41 were in the CM group, 48 in the ACM group, and 28 in the SOC group. There were 21 withdrawals, but seven had reached the first primary end point. Complete re-epithelialization of the ulcer by 12 weeks occurred in 59% of the 117 total participants: 49% in the CM group, 69% in the ACM group, and 57% in the SOC group (P = 0.16 by \u03c72 test). At 28 weeks, 25 participants (61%) in the CM group, 27 (56%) in the ACM group, and 18 (64%) in the SOC group had healed (P = 0.78). No differences were found in wound recidivism or adverse event occurrence between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>No difference in efficacy was found between SOC, ACM, and CM, suggesting that SOC can reduce the economic burden of diabetic foot ulcer treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc24-1233","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T17:00:03Z","timestamp":1746637203000},"page":"966-973","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":9,"title":["Cellular Versus Acellular Matrix Products for Diabetic Foot Ulcer Treatment: The Dermagraft and Oasis Longitudinal Comparative Efficacy Study (DOLCE)\u2014A Randomized Clinical Trial"],"prefix":"10.2337","volume":"48","author":[{"given":"Harrison","family":"Shawa","sequence":"first","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"},{"name":"2Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanjot","family":"Kaur","sequence":"additional","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"},{"name":"3Department of Dermatology, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Tchanque-Fossuo","sequence":"additional","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"},{"name":"3Department of Dermatology, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Lev-Tov","sequence":"additional","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"},{"name":"3Department of Dermatology, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"West","sequence":"additional","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallas Sulgi","family":"Lim","sequence":"additional","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3074-5930","authenticated-orcid":false,"given":"Nuen Tsang","family":"Yang","sequence":"additional","affiliation":[{"name":"4Division of Biostatistics, University of California Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6273-7954","authenticated-orcid":false,"given":"Mirabel","family":"Dafinone","sequence":"additional","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"},{"name":"5School of Medicine, University of Nevada Reno, Reno, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawlings Everett","family":"Lyle","sequence":"additional","affiliation":[{"name":"3Department of Dermatology, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Shang","family":"Li","sequence":"additional","affiliation":[{"name":"4Division of Biostatistics, University of California Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rocke","sequence":"additional","affiliation":[{"name":"4Division of Biostatistics, University of California Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8358-5061","authenticated-orcid":false,"given":"Sara","family":"Dahle","sequence":"additional","affiliation":[{"name":"3Department of Dermatology, University of California Davis, Sacramento, CA"},{"name":"6Podiatry Section, VA Northern California Health Care System, Mather, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-0858","authenticated-orcid":false,"given":"Roslyn Rivkah","family":"Isseroff","sequence":"additional","affiliation":[{"name":"1Dermatology Section, VA Northern California Health Care System, Mather, CA"},{"name":"3Department of Dermatology, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2025052014522282400_B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2337\/dci22-0043","article-title":"Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers","volume":"46","author":"McDermott","year":"2023","journal-title":"Diabetes Care"},{"key":"2025052014522282400_B2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2023.10578","article-title":"Diabetic foot ulcers: a review","volume":"330","author":"Armstrong","year":"2023","journal-title":"JAMA"},{"key":"2025052014522282400_B3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.12968\/jowc.2020.29.8.464","article-title":"Diabetic foot ulcer management in a multidisciplinary foot centre: one-year healing, amputation and mortality rate","volume":"29","author":"Van","year":"2020","journal-title":"J Wound Care"},{"key":"2025052014522282400_B4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13047-020-00383-2","article-title":"Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer","volume":"13","author":"Armstrong","year":"2020","journal-title":"J Foot Ankle Res"},{"key":"2025052014522282400_B5","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"2025052014522282400_B6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1464-5491.2004.01375.x","article-title":"Healing diabetic neuropathic foot ulcers: are we getting better?","volume":"22","author":"Margolis","year":"2005","journal-title":"Diabet Med"},{"key":"2025052014522282400_B7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1742-481X.2009.00585.x","article-title":"Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study","volume":"6","author":"Reyzelman","year":"2009","journal-title":"Int Wound J"},{"key":"2025052014522282400_B8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2337\/dc06-2043","article-title":"Rate of healing of neuropathic ulcers of the foot in diabetes and its relationship to ulcer duration and ulcer area","volume":"30","author":"Ince","year":"2007","journal-title":"Diabetes Care"},{"key":"2025052014522282400_B9","first-page":"CD011255","article-title":"Skin grafting and tissue replacement for treating foot ulcers in people with diabetes","volume":"2","author":"Santema","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025052014522282400_B10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.suc.2020.05.006","article-title":"Biologic and synthetic cellular and\/or tissue-based products and smart wound dressings\/coverings","volume":"100","author":"Abdo","year":"2020","journal-title":"Surg Clin North Am"},{"key":"2025052014522282400_B11","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2337\/diacare.26.6.1701","article-title":"The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial","volume":"26","author":"Marston","year":"2003","journal-title":"Diabetes Care"},{"key":"2025052014522282400_B12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2337\/diacare.19.4.350","article-title":"Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers","volume":"19","author":"Gentzkow","year":"1996","journal-title":"Diabetes Care"},{"key":"2025052014522282400_B13","first-page":"283","article-title":"Open-label extension phase of a chronic diabetic foot ulcer multicenter, controlled, randomized clinical trial using cryopreserved placental membrane","volume":"30","author":"Lavery","year":"2018","journal-title":"Wounds"},{"key":"2025052014522282400_B14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/iwj.12329","article-title":"The efficacy and safety of Grafix for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial","volume":"11","author":"Lavery","year":"2014","journal-title":"Int Wound J"},{"key":"2025052014522282400_B15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00129334-200506000-00012","article-title":"Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers","volume":"18","author":"Niezgoda","year":"2005","journal-title":"Adv Skin Wound Care"},{"key":"2025052014522282400_B16","unstructured":"WellRx\n          . Dermagraft. Accessed 11 October 2024. Available fromhttps:\/\/www.wellrx.com\/prescriptions\/dermagraft"},{"key":"2025052014522282400_B17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1525-1594.1997.tb00476.x","article-title":"A metabolically active human dermal replacement for the treatment of diabetic foot ulcers","volume":"21","author":"Naughton","year":"1997","journal-title":"Artif Organs"},{"key":"2025052014522282400_B18","first-page":"111","article-title":"Living cells or collagen matrix: which is more beneficial in the treatment of diabetic foot ulcers?","volume":"20","author":"Landsman","year":"2008","journal-title":"Wounds"},{"key":"2025052014522282400_B19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/wound.2018.0829","article-title":"Why is calculating the \u201ctrue\u201d cost-to-heal wounds so challenging?","volume":"7","author":"Carter","year":"2018","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"2025052014522282400_B20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-14-8","article-title":"Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial","volume":"14","author":"Lev-Tov","year":"2013","journal-title":"Trials"},{"key":"2025052014522282400_B21","first-page":"E18","article-title":"Cellular versus acellular grafts for diabetic foot ulcers: altering the protocol to improve recruitment to a comparative efficacy trial","volume":"100","author":"Tchanque-Fossuo","year":"2017","journal-title":"Cutis"},{"key":"2025052014522282400_B22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/term.2884","article-title":"Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: interim results of a comparative efficacy randomized controlled trial","volume":"13","author":"Tchanque-Fossuo","year":"2019","journal-title":"J Tissue Eng Regen Med"},{"key":"2025052014522282400_B23","first-page":"CD003557","article-title":"Antibiotics and antiseptics for venous leg ulcers","volume":"2014","author":"O\u2019Meara","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025052014522282400_B24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/iwj.13560","article-title":"Efficacy of topical cadexomer iodine treatment in chronic wounds: systematic review and meta-analysis of comparative clinical trials","volume":"18","author":"Woo","year":"2021","journal-title":"Int Wound J"},{"key":"2025052014522282400_B25","article-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2014"},{"key":"2025052014522282400_B26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/wrr.12391","article-title":"WHS guidelines update: diabetic foot ulcer treatment guidelines","volume":"24","author":"Lavery","year":"2016","journal-title":"Wound Repair Regen"},{"key":"2025052014522282400_B27","first-page":"29","article-title":"Updating the diabetic foot treatment algorithm: recommendations on treatment using advanced medicine and therapies","volume":"30","author":"Blume","year":"2018","journal-title":"Wounds"},{"key":"2025052014522282400_B28","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2015.10.003","article-title":"The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine","volume":"63","author":"Hingorani","year":"2016","journal-title":"J Vasc Surg"},{"key":"2025052014522282400_B29","first-page":"18","article-title":"Small intestinal submucosa wound matrix and full-thickness venous ulcers: preliminary results","volume":"16","author":"Demling","year":"2004","journal-title":"Wounds"},{"key":"2025052014522282400_B30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jvs.2005.01.042","article-title":"Effectiveness of an extracellular matrix graft (OASIS wound matrix) in the treatment of chronic leg ulcers: a randomized clinical trial","volume":"41","author":"Mostow","year":"2005","journal-title":"J Vasc Surg"},{"key":"2025052014522282400_B31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/diacare.24.2.290","article-title":"Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial","volume":"24","author":"Veves","year":"2001","journal-title":"Diabetes Care"},{"key":"2025052014522282400_B32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.12968\/jowc.2015.24.3.149","article-title":"Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular\/tissue-derived products","volume":"24","author":"Gilligan","year":"2015","journal-title":"J Wound Care"},{"key":"2025052014522282400_B33","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.12968\/jowc.2016.25.Sup10.S8","article-title":"A comparative analysis of skin substitutes used in the management of diabetic foot ulcers","volume":"25","author":"Martinson","year":"2016","journal-title":"J Wound Care"},{"key":"2025052014522282400_B34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1089\/wound.2015.0645","article-title":"The management of diabetic foot ulcers with porcine small intestine submucosa tri-layer matrix: a randomized controlled trial","volume":"4","author":"Cazzell","year":"2015","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"2025052014522282400_B35","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc08-0771","article-title":"Use of pressure offloading devices in diabetic foot ulcers: do we practice what we preach?","volume":"31","author":"Wu","year":"2008","journal-title":"Diabetes Care"},{"key":"2025052014522282400_B36","doi-asserted-by":"crossref","first-page":"108621","DOI":"10.1016\/j.diabres.2020.108621","article-title":"Cumulative long-term recurrence of diabetic foot ulcers in two cohorts from centres in Germany and the Czech Republic","volume":"172","author":"Ogurtsova","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2025052014522282400_B37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/1932296815584796","article-title":"Illustration of cost saving implications of lower extremity nerve decompression to prevent recurrence of diabetic foot ulceration","volume":"9","author":"Rankin","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"2025052014522282400_B38","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2337\/dc12-0200","article-title":"Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade","volume":"35","author":"Morbach","year":"2012","journal-title":"Diabetes Care"},{"key":"2025052014522282400_B39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diacare.26.2.491","article-title":"Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology","volume":"26","author":"Moulik","year":"2003","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/6\/966\/806092\/dc241233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/6\/966\/806092\/dc241233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T18:52:32Z","timestamp":1747767152000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/6\/966\/158230\/Cellular-Versus-Acellular-Matrix-Products-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc24-1233","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}